The company's main business is producing, outsourcing, manufacturing, and distributing skincare, color cosmetics, and healthcare products under six major brands, three of which are held by the company, namely Rojukiss, Best korea, and Sis2Sis. While two of them are owned by subsidiary company, namely PhD K-Derma, and VAILL COVITRAP with over 100 SKUs in our product portfolio. The Company has conducted R&D and developed formulas and packaging jointly with manufacturers to be distributed through both domestic and international sales channels
| 3M23 | 3M22 | 2022 | 2021 |
|---|
| Revenues | 207.18 | 172.57 | 940.06 | 776.05 |
| Expenses | 154.53 | 146.10 | 764.84 | 629.80 |
| Net Profit (Loss) | 26.95 | 19.60 | 123.71 | 118.57 |
| Assets | 1,330.27 | 1,166.92 | 1,297.08 | 1,048.73 |
| Liabilities | 270.13 | 186.06 | 278.55 | 118.81 |
| Shareholders' Equity | 991.84 | 951.21 | 964.06 | 929.92 |
| Operating | 42.50 | 54.90 | 85.54 | 177.95 |
| Investing | -1.04 | -7.40 | -111.03 | -187.74 |
| Financing | 26.01 | -5.82 | -89.57 | 370.52 |
| EPS (Baht) | 0.04 | 0.03 | 0.21 | 0.20 |
| GP Margin (%) | 52.33 | 52.41 | 51.97 | 53.57 |
| NP Margin (%) | 19.68 | 11.16 | 15.73 | 15.28 |
| D/E Ratio (x) | 0.25 | 0.19 | 0.27 | 0.13 |
| ROE (%) | 13.49 | 10.24 | 13.06 | 17.47 |
| ROA (%) | 16.81 | 10.02 | 15.61 | 16.08 |
- Uplifting the company's products to be the "Top of Mind Brand" through advertising and marketing activities, together with the development of consumer-responsive product innovation
- Expanding distribution channels for color cosmetic products under the Sis2Sis brand
- Enhancing sales channels both Offline and Online
- Growing in overseas markets by planning strategies and setting appropriate business models to accelerate growth and enhance competitiveness
- Adapting strategic plans for health products to the circumstances at hand
KISS is committed to operating business in line with a sustainable development approach as well as considering all relevant stakeholders in tune with good governance principles. We support sustainable development through the foundation of our business operations based on ESG principles, which encompass the environmental social, and governance dimensions. The organization's sustainability policy was created to guide its strategy and ability to do business in a socially responsible manner, under the mission to be a global leader in the future beauty and health business in Asia will be reignited (Health & Beauty for the Future of Asia). For further information, please visit our website. https://hub.optiwise.io/storage/103/annual-report/2022/e-book/th/index.html
The company’s started to expand business into healthcare market under trademarked name Vaill CoviTRAP TM Anti-CoV Nasal Spray which has been widely accepted by health-conscious consumers especially during the Covid-19 outbreak. This is considered as a further move toward becoming a leader in Asia’s health & beauty business for the future.
The revenue from sales and services in Q1/2023 was 207.0 million baht, an increase of 22.5% YoY but a drop of 38.5% QoQ mainly from
- Revenue from Domestic increased by 10% YoY from Modern Trade, which increased from both Convenience stores and Hypermarket channels, driven by the launch of new products (NPDs) and online and offline marketing activities. In terms of nasal spray, there were no transactions in Q1/2022, resulting in a 100% increase in this quarter.
- Revenue from Overseas decreased by 77% YoY due to lower sales from Indonesia and Vietnam. However, the company plans on launching new products to differentiate itself from others in the current competitive market.
- Total revenue decreased by 38.5% QoQ from both core business and slower sales of nasal spray
EBITDA was 53.6 million baht, an increase of 95.9% YoY but decreased by 32.0 QoQ. While Net Profit was 40.8 million baht, an increase of 111.8% YoY but a decrease of 33.2% QoQ.
2020
- Launched new skin beauty supplement under “Rojukiss”
- Signed with the distributor of the company's products in Indonesia and the Philippines.
- Registered as a public company: Increase registered capital to prepare for an IPO and expand business continuously.
2021
- Release new products to export for sale to Indonesia.
- Release new products to export for sale to Vietnam
2022
- Investment in Hibiocy Company Limited to expand its business into Health product innovations
- Officially launched “VAILL COVITRAP Anti-CoV” Nasal Spray under the management of Hibiocy Co., Ltd. (“HIB”)
The Company has put in place risk management system and process throughout the organization which is in line with business strategies and goals. The Company assigns responsibilities for risk control and review the risk measures annually by setting guidelines that cover the assessment in the following main topics:
- Strategic & Brand Risk
- Operational & Supply Chain Risk
- Financial & Liquidity Risk
- Information Technology Risk
- Organizational Risk
- Compliance Risk
WATSONS HWB AWARDS 2022 Best Rising Star Brand of the Year- Facial Skin Care
| as of 31/03/23 | KISS | PERSON | SET |
|---|---|---|---|
| P/E (X) | 33.71 | 18.46 | 19.27 |
| P/BV (X) | 4.33 | 1.09 | 1.59 |
| Dividend yield (%) | 2.01 | 5.49 | 2.91 |
| 31/03/23 | 30/12/22 | 30/12/21 | |
|---|---|---|---|
| Market Cap (MB) | 4,170.00 | 5,100.00 | 6,300.00 |
| Price (B/Share) | 6.95 | 8.50 | 10.50 |
| P/E (X) | 33.71 | 48.87 | 49.59 |
| P/BV (X) | 4.33 | 5.49 | 6.93 |
